BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

Doer Bio Begins Phase 2 Trial of Tri-Agonist DR10624 for MASLD and MASH Treatment

Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and...

April 24, 2025 | News

Sichuan Kelun-Biotech Secures FDA IND Clearance for First-in-Class ADC SKB518

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has been granted the clearance of investigational new dru...

April 22, 2025 | News

Rona Therapeutics Secures IND Approval in China for siRNA-Based Hypertension Therapy RN1871

Rona Therapeutics, a biotechnology company pioneering innovative RNA-targeted therapies, announced that the Investigational New Drug (IND) application for&...

April 22, 2025 | News

China Rises as Global Force in Blood Purification Tech at BPPC Annual Conference

Blood Purification Professional Committee (BPPC) of the China Medical Device Industry Association (CMDIA) gathered in Liuyang, Hunan, for its annual c...

April 21, 2025 | News

Akeso Secures NMPA Approval for Ebdarokimab in Moderate-to-Severe Plaque Psoriasis

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, ...

April 21, 2025 | News

WuXi Biologics Achieves Asia’s First Commercial PPQ Milestone with 3 x 5,000L Single-Use Bioreactors

- The campaign marks the successful commercial-scale PPQ completion of Asia's first 3 X 5,0...

April 21, 2025 | News

VelaVigo Bio Signs $440M Global Licensing Deal with Ollin Biosciences for First-in-Class Bispecific Antibody VBS-102

VelaVigo Bio, the U.S. subsidiary of VelaVigo Cayman Limited (VelaVigo), a biotech company with a robust discovery and development platform of multi-specif...

April 18, 2025 | News

Porton Advanced Supports IND Approval of Tasly’s Dual-Targeting CAR-T Therapy for Recurrent Glioblastoma

Porton Advanced proudly announces its CDMO support for Tasly Pharmaceutical Co., Ltd.'s innovative CAR-T therapy, "P134 Cell Injection," which has received...

April 17, 2025 | News

Fangzhou Launches AI-Driven Hepatitis Training Center with Guangdong Institute at Liver Disease Forum 2025

Fangzhou Inc., a leader in AI-driven healthcare solutions, partnered with the Guangdong Provincial Liver Disease Institute at the 2025 Greater Bay Area Int...

April 17, 2025 | News

XellSmart Receives IND Approval from FDA for iPSC-Derived Cell Therapy in Parkinson’s Disease

In January 2025 (U.S. time), the U.S. Food and Drug Administration (FDA) officially approved the Investigational New Drug (IND) application submi...

April 16, 2025 | News

Belief BioMed and Takeda China Announce NMPA Approval of China’s First Gene Therapy for Hemophilia B

Belief BioMed ("BBM") and Takeda China jointly announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has be...

April 11, 2025 | News

Darnatein Secures First International Patent in China for AI-Engineered Osteoarthritis Drug Technology

Darnatein, a wholly-owned subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), today announces that it has successfully secured an additional international pat...

April 10, 2025 | News

RemeGen’s Telitacicept Shows Best-in-Class Efficacy in Phase 3 Trial for Generalized Myasthenia Gravis

On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept...

April 09, 2025 | News

China’s AIM Vaccine Set to Launch World’s First Serum-Free Rabies Vaccine Following Regulatory Acceptance

AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, announced on April 7, 2025 that the company's research and development of the se...

April 08, 2025 | News

Stay Connected